Published in Cancer Immunol Immunother on April 01, 1998
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 2.09
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med (1999) 1.82
Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.61
Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res (2000) 1.49
Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med (2004) 1.22
Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem (2007) 1.22
Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer (2007) 1.13
Personalized dendritic cell-based tumor immunotherapy. Immunotherapy (2010) 1.08
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Effect of a cancer vaccine prepared by fusions of hepatocarcinoma cells with dendritic cells. World J Gastroenterol (2001) 0.98
Direct stimulation of T cells by membrane vesicles from antigen-presenting cells. Proc Natl Acad Sci U S A (2006) 0.96
Antitumor activities of human dendritic cells derived from peripheral and cord blood. World J Gastroenterol (2002) 0.93
An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine (2006) 0.90
Accessibility of N-acyl-D-mannosamines to N-acetyl-D-neuraminic acid aldolase. Carbohydr Res (2004) 0.90
Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther (2010) 0.85
Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst (2004) 0.83
Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol (2013) 0.82
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
The balance between immunity and tolerance: the role of Langerhans cells. Cell Mol Life Sci (2009) 0.79
Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. J Cancer Res Clin Oncol (2005) 0.77
Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model. PLoS One (2011) 0.77
Induction of tolerance to immunogenic tumor antigens associated with lymphomagenesis in HOX11 transgenic mice. Proc Natl Acad Sci U S A (2000) 0.76
Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. Int J Mol Sci (2016) 0.76
New dimensions in vaccinology: A new insight. Indian J Clin Biochem (2005) 0.75
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med (1996) 3.01
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 2.99
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med (1992) 1.93
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science (1992) 1.76
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res (2000) 1.68
Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64
Ambulatory surgical management of breast carcinoma using paravertebral block. Ann Surg (1995) 1.62
Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol (2001) 1.58
HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol (1989) 1.57
Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg (1998) 1.43
Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet (1988) 1.38
Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol (2001) 1.36
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol (2000) 1.32
Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res (2001) 1.30
GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol (1989) 1.29
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood (2000) 1.26
Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol (2000) 1.23
Role of proteolytic enzyme in the prevention of postoperative intraperitoneal adhesions. Arch Surg (1974) 1.22
Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol (1990) 1.21
HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res (1994) 1.20
Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.18
Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8-A resolution. Proc Natl Acad Sci U S A (1996) 1.16
RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest (2000) 1.12
Engineering the hydrophobic pocket of carbonic anhydrase II. Biochemistry (1991) 1.09
Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost (2000) 1.09
Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. Eur J Immunol (1998) 1.08
Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 1.06
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther (2009) 1.05
Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses (1989) 1.05
Coverage, utilization and barriers to cataract surgical services in rural South India: results from a population-based study. Public Health (2007) 1.04
Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. J Immunol (2000) 1.02
Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection. AIDS Res Hum Retroviruses (2000) 1.00
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer (2009) 0.98
Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res (1998) 0.98
Two-generation marker-aided backcrossing for rapid conversion of normal maize lines to quality protein maize (QPM). Theor Appl Genet (2005) 0.96
Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br J Cancer (2011) 0.96
Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. J Virol (1993) 0.96
Surgical management of chronic pulmonary embolism. Ann Surg (1985) 0.95
Structure and energetics of a non-proline cis-peptidyl linkage in a proline-202-->alanine carbonic anhydrase II variant. Biochemistry (1993) 0.95
Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology (1994) 0.95
The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. Anaesthesia (2011) 0.94
Acute perforation of small intestine due to tuberculosis. Aust N Z J Surg (1983) 0.94
Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery (1994) 0.93
RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther (2000) 0.93
Recognizing DNA in the library. Nature (2000) 0.92
Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol (1994) 0.92
Primary actinomycosis of the abdominal wall. Aust N Z J Surg (1975) 0.91
MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res (1996) 0.91
Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol (1994) 0.91
Total synthesis of cryptophycin-24 (Arenastatin A) amenable to structural modifications in the C16 side chain. J Org Chem (2000) 0.91
Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging (1997) 0.91
AIDS-related malignancies. Ann Med (1998) 0.90
Utility of Doppler color flow imaging for identification of femoral arterial complications of cardiac catheterization. Am Heart J (1989) 0.90
Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer (1999) 0.89
Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. Surgery (1992) 0.88
Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol (2001) 0.87
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol (2010) 0.87
Mapping QTLs for popping ability in a popcorn x flint corn cross. Theor Appl Genet (2006) 0.87
Autoantibodies in thromboangiitis obliterans (Buerger's disease). Angiology (1982) 0.87
Prevalence of blindness and its causes among those aged 50 years and above in rural Karnataka, South India. Trop Doct (2007) 0.84
Surrogate markers of response to cancer immunotherapy. Expert Opin Biol Ther (2001) 0.84
Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses (1988) 0.84
Coagulopathy associated with massive cell salvage transfusion following aortic surgery. Perfusion (2011) 0.84
Effects of cyclosporine on human B-cell lymphoma development in vivo. Surg Oncol (1992) 0.83
Clinical applications of dendritic cell vaccines. Curr Opin Mol Ther (2000) 0.83
Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery (1993) 0.83
Involvement of an ATP-dependent peptide chaperone in cross-presentation after DNA immunization. J Immunol (2000) 0.82
Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother (2000) 0.82
Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother (1998) 0.82
A quantitative trait locus for reduced culm internode length in barley segregates as a Mendelian gene. Theor Appl Genet (2008) 0.81
Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Ther (2011) 0.81
T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Ann Surg Oncol (1994) 0.81
The role of IL-13 in the generation of dendritic cells in vitro. J Immunother (1999) 0.81
MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. Br J Cancer (2009) 0.81
Radiographic findings in pulmonary hypertension from unresolved embolism. AJR Am J Roentgenol (1985) 0.81
External exposure to radionuclides accumulated in shoreline sediments with an application to the lower Clinch River. Health Phys (2000) 0.81
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. J Hematother Stem Cell Res (1999) 0.80
Cytomegalovirus sialadenitis in patients with the acquired immunodeficiency syndrome: a potential diagnostic pitfall with fine-needle aspiration cytology. Diagn Cytopathol (1994) 0.80
Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery (1996) 0.80
Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine. AIDS Res Hum Retroviruses (1987) 0.79
Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease. Dev Biol Stand (1990) 0.79
Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. Ann Surg Oncol (1999) 0.78
Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. Circulation (1995) 0.78
Mouse rhodanese gene (Tst): cDNA cloning, sequencing, and recombinant protein expression. Biochem Biophys Res Commun (1995) 0.78
Immunotherapy of cancer using dendritic cells. Cytokines Cell Mol Ther (1998) 0.78
Optimizing dendritic cell function by genetic modification. J Natl Cancer Inst (2000) 0.78
Prospects for development of a vaccine against HTLV-III-related disorders. AIDS Res Hum Retroviruses (1987) 0.78
Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res (2000) 0.78
Immunotherapy of cancer with dendritic cell-based vaccines. Gene Ther (1998) 0.77